Tumor-reactive antibodies evolve from non-binding and autoreactive precursors.
Mazor RD, Nathan N, Gilboa A, Stoler-Barak L, Moss L, Solomonov I, Hanuna A, Divinsky Y, Shmueli MD, Hezroni H, Zaretsky I, Mor M, Golani O, Sabah G, Jakobson-Setton A, Yanichkin N, Feinmesser M, Tsoref D, Salman L, Yeoshoua E, Peretz E, Erlich I, Cohen NM, Gershoni JM, Freund N, Merbl Y, Yaari G, Eitan R, Sagi I, Shulman Z.
Mazor RD, et al. Among authors: feinmesser m.
Cell. 2022 Mar 31;185(7):1208-1222.e21. doi: 10.1016/j.cell.2022.02.012. Epub 2022 Mar 18.
Cell. 2022.
PMID: 35305314
Free article.